Advertisement

Epidemiology, Etiology, and Histopathology

  • Jungyo Suh
Chapter

Abstract

Urothelial carcinoma is a cancer which originates in the urothelium, which covers the internal layer of the bladder, ureter, urethra, and renal pelvis. Prevalence of urothelial carcinoma is relatively higher in developed country. Incidence is on average three times higher in the male population; however mortality is higher in the female population. Smoking and occupational exposure to aromatic amine compounds are the most important environmental factors. Most frequently founded chromosomal abnormality is loss of chromosome 9, and FGFR, TP53, and PI3K gene mutations are important pathways in bladder cancer carcinogenesis. According to epidemiological difference between male and female population, recent genetic study focused on sex hormone receptor as prognostic factor.

Keywords

Urothelial carcinoma Epidemiology Etiology Genetic factor Environmental factor 

References

  1. 1.
    Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108.CrossRefGoogle Scholar
  2. 2.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.  https://doi.org/10.3322/caac.21262.CrossRefPubMedGoogle Scholar
  3. 3.
    Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nat Rev Dis Prim. 2017;3:1–19.  https://doi.org/10.1038/nrdp.2017.22.CrossRefGoogle Scholar
  4. 4.
    Li H-T, Duymich CE, Weisenberger DJ, Liang G. Genetic and epigenetic alterations in bladder cancer. Int Neurourol J. 2016;20:S84–94.  https://doi.org/10.5213/inj.1632752.376.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Höglund M. The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstacles. Urol Oncol Semin Orig Investig. 2012;30:533–40.  https://doi.org/10.1016/j.urolonc.2012.04.001.CrossRefGoogle Scholar
  6. 6.
    Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene. 2000;19:6317–23.  https://doi.org/10.1038/sj.onc.1204022.CrossRefPubMedGoogle Scholar
  7. 7.
    Höglund M, Mitelman F, Mandahl N, Fadl-Elmula I, Säll T, Heim S. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res. 2001;61:8241–6.PubMedGoogle Scholar
  8. 8.
    Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15:25–41.  https://doi.org/10.1038/nrc3817.CrossRefPubMedGoogle Scholar
  9. 9.
    van Rhijn BWG, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012;187:310–4.  https://doi.org/10.1016/j.juro.2011.09.008.CrossRefPubMedGoogle Scholar
  10. 10.
    Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, de Medina SGD, van Rhijn B, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955–9.  https://doi.org/10.1016/S0002-9440(10)64665-2.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet. 2010;42:415–9.  https://doi.org/10.1038/ng.558.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003;63:8108–12.PubMedGoogle Scholar
  13. 13.
    Wallerand H, Bakkar AA, de Medina SGD, Pairon JC, Yang YC, Vordos D, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis. 2005;26:177–84.  https://doi.org/10.1093/carcin/bgh275.CrossRefPubMedGoogle Scholar
  14. 14.
    Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–22.  https://doi.org/10.1038/nature12965.CrossRefGoogle Scholar
  15. 15.
    Bassett JC, Gore JL, Kwan L, Ritch CR, Barocas DA, Penson DF, et al. Knowledge of the harms of tobacco use among patients with bladder cancer. Cancer. 2014;120:3914–22.  https://doi.org/10.1002/cncr.28915.CrossRefPubMedGoogle Scholar
  16. 16.
    Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311–22.  https://doi.org/10.1046/j.1523-5394.2002.106011.x.CrossRefPubMedGoogle Scholar
  17. 17.
    Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008;180:2005–10.  https://doi.org/10.1016/j.juro.2008.07.038.CrossRefPubMedGoogle Scholar
  18. 18.
    Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2008;174:107–11.  https://doi.org/10.1016/j.juro.2008.03.131.CrossRefGoogle Scholar
  19. 19.
    Michaud DS. Chronic inflammation and bladder cancer. Urol Oncol. 2007;25:260–8.  https://doi.org/10.1016/j.urolonc.2006.10.002.CrossRefPubMedGoogle Scholar
  20. 20.
    Salem HK, Mahfouz S. Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade. Urology. 2012;79:379–83.  https://doi.org/10.1016/j.urology.2011.08.072.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Jungyo Suh
    • 1
  1. 1.Department of UrologySeoul National University HospitalSeoulSouth Korea

Personalised recommendations